Purpose: In this study, we present the clinical implementation of a novel transoral balloon centering esophageal applicator (BCEA) and the initial clinical experience in high-dose-rate (HDR) brachytherapy treatment of esophageal cancer, using this applicator.
Purpose
Esophageal cancer develops in the mucosa of the esophagus and spreads towards the muscle layer. The nonsurgical treatment for localized, deeply invasive esophageal cancer has been external beam radiation therapy (EBRT) and concurrent chemotherapy [1] . Recently, intraluminal brachytherapy showed a strong potential for the improvement of the therapeutic ratio [2] . It was found that the fractionated high-dose-rate (HDR) brachythera--ing was found for advanced unresectable esophageal cancer in previously irradiated patients [5, 6] . Hihg-dose-rate brachytherapy may be a useful salvage treatment option for inoperable patients diagnosed with local esophageal cancer [6] . Although better local control can be achieved of acute morbidity [4, 7] and late morbidity, especially in the setting of recurrence cancer [4] . It was found that the moderate dose of EBRT and HDR brachytherapy could give a better local response than EBRT alone [8] . The results in a large cohort of patients indicated that HDR brachytherapy alone was an effective method for the palliation of advanced esophageal cancer [9] . Similar long-term results were reported in favor of treatments involving concurrent chemoradiotherapy followed by HDR brachytherapy [10] . Although brachytherapy was found to be preferable, there are studies (such as [11, 12] ) suggesting that stent placement may play an important role for the palliation of disease. In that case, the prognostic models were used as evidence-based tools in dewas reported to be improved in patients treated with the HDR brachytherapy. Recent studies suggested the usage of 252 Cf neutron brachytherapy combined with EBRT for esophageal cancer. The treatment resulted in favorable local control and long-term survival rates with tolerable side effects [13] .
Patient selection, timing of brachytherapy, and dose continue to urge caution in using brachytherapy treat--ment [10, 14, 15] . Therefore, the addition of brachytherapy, to well-selected patients [15] .
For that reason, the clinical implementation and accuracy in dose delivery is crucial for favorable treatment outcomes. The radiation dose is delivered using esophageal transoral or transnasal applicators with an external diameter of 0.6-1 cm. Ideally, the single channel applicator needs to be placed centrally in the lumen of the esophagus; however, there exists a possibility that the applicator will be closer to one side of the lumen, delivering a larger dose to the epithelium, lamina propria, and muscularis mucosa, resulting in local esophageal and esophageal ulceration are the common late toxicities of HDR brachytherapy [16] . A possible difference in the delivered dose is caused by disagreements in the choice of the dose point (i.e. mucosal surface or certain distance from the central line of the applicator) in various institutions, as reported in [17] . For instance, it was reported in the long-term experience with esophageal brachytherapy treatment [18] that radiation was delivered at a level of 5 mm below the surface of the mucosa. However, no correlation was found between the post-treatment complications and the diameter of the brachytherapy applicator [19] . In most of the HDR brachytherapy treatments, 3D treatment plans were generated using computed tomography (CT) images; however, magnetic resonance imaging (MRI) can be used to assist the localization of the tumor and the applicator [20] . The treatment planning for the esophageal cancer patient is performed using the TG-43 formalism [21] , since the dose calculation ac--dium [22] . Overall, this HDR treatment is demonstrated and recurrent esophageal cancer in inoperable patients [23, 24] . The authors concluded that dose escalation with larger diameter applicators may allow for improved thertolerances [23] . The latest research in the combined approach (EBRT and HDR) to palliation in esophageal canreported in [25, 26] .
The purpose of the study is to report the initial experience in the treatment of the locally advanced esophageal carcinoma with HDR brachytherapy, using a novel transoral balloon centering esophageal applicator (BCEA; E-APP™, Ancer Medical, USA). In this study, we report the commissioning procedure, treatment planning, HDR brachytherapy treatment delivery, and initial patient response using the novel BCEA. The experience in the treatment of esophageal cancer using a standard intraluminal esophageal applicator (EA) was summarized in [27] . The comparison between the standard EA and the BCEA -ing the treatment of the patient diagnosed with esophageal cancer.
Material and methods

Patient
Initially, the patient was diagnosed with an adenocarcinoma of the distal esophagus. The pathological chemoradiotherapy (50 Gy) preoperatively for locally advanced esophageal carcinoma, followed by a partial esophagectomy. Two months after surgery, the patient was diagnosed with a recurrent neoplasm of the middle third of the esophagus, as recurrent adenocarcinoma at the anastomosis. Computed tomography/positron emission tomography (CT/PET) imaging showed an avid lesion at the anastomosis. A combined external beam and brachytherapy approach was created as salvage therapy. radiation therapy to the maximal normal tissue dose constraint. At the endoscopic reevaluation after therapy, there was persistent tumor of 5.5 cm in greatest dimension (gross tumor volume). High-dose-rate brachytherafor the recurrence. The clinical target length was 9 cm, so the total treatment length (planning target volume) includes a 3 cm margin both proximally and distally, which resulted in a total of 15 cm treatment length.
Acceptance and commissioning of the balloon centering esophageal applicator
per gastrointestinal region, we used the novel disposable balloons (Figure 1 ) to allow for the central placement of the radioactive source during treatment. The applicator was designed for treatment lengths greater than 10 cm. The BCEA allows for the treatments outside the balloon region with the constraint where the BCEA becomes similar to the standard EA. Therefore, the dose optimization outside the balloon region should be avoided due to the complicated position reproducibility. A diameter of the BCEA is 0.5 cm. The visibility of the catheter on the CT images is obtained with 12 CT and MRI compatat the tip of the BCEA, the next one is 0.3 cm proximal, delivery.
cator was used for acceptance testing and commissioning. During the acceptance testing, the performance evaluation and familiarization with the proper function of the BCEA was conducted. The following was evaluated: the dimensions, catheter diameter, balloon -stability, and the absolute and relative positioning of the applicator was commissioned and tested for clinical implementations. The following was tested: a) visiassure the proper placement; b) repeatability, consissource positioning in the applicator using the source -Chromic TM , Ashland, Covington, USA). In addition, the the exterior side of the catheters were tested for proper source placement in the clinical target. The additional goal of this test was to determine the reproducibility of the offset. Due to the possibility of the subjective judgment for some tests, the data were analyzed by three inif an interobserver agreement was established.
Applicator placement
The BCEA design includes two lumens: a central lumen to contain the HDR radioactive source, and the second lumen through which the guide wire passes.
scope would be placed via the anesthetized nose past turbinates and nasopharynx behind the larynx and into the esophagus, this applicator was placed transorally. This avoided the customary trauma, bleeding, and pain. The scope was placed transorally and the guide wire passed through the side port. The scope was removed and the applicator was placed over the guide wire. The scope was then reinserted via the mouth the end of the procedure, the guide wire and the scope were removed.
Treatment planning
For the treatment planning, we used Oncentra Brachy plan was generated using a CT image set with a 1.25 mm catheter. The prescription dose for the HDR treatments was 15 Gy in 3 fractions to the distal esophagus with a 5 cm offset from the end of the applicator. The treatThe treatment (target) length was 15 cm, which resulted in 31 dwell positions having a step size of 0.5 cm. The treatwith 1-2 cm distal, and proximal margin determined by -cosal surface or a certain distance from the central line of the applicator with identical dwell times along the treatment length. This was mostly done to minimize the uncertainties in dose delivery related to the positioning of the EA inside the esophagus. The BCEA positions the catheter the treatment plan can be additionally optimized for improved dose distribution and conformality. The prescription dose was planned to be delivered to the diameter of 1 cm with respect to the central catheter with an additional optimization to avoid the critical anatomical structures such as the heart, lung, pharyngeal constrictor, and spine. The dose calculation was performed using the TG-43 formalism that includes the anisotropy corrections. Heterogeneity corrections were not included in the brachytherapy dose calculation.
Results
Acceptance and commissioning of the balloon centering esophageal applicator the catheter diameter was 0.5 cm. The diameter of the in-3 of sterile water was - The absolute positioning of the source at the most distal position was crucial to establish the maximum treatment -used. The experimental setup was presented in Figure 3 . The source was sent to various distances initially determined using the source position simulator. The purpose of this test was to determine the exact position of the source at its distal end. The test results were presented in Figure 4 . It was revealed that the distal position of the source 192 Ir (source extension) was 1270 mm for the microSelectron V.2. afterloader (Nucletron, an was attached to the afterloader and a 1270 mm source extension was used, the additional test results showed sub-millimeter accuracy in the source positioning of the whole system. The value obtained in this test is entered into the treatment planning system to avoid the geometric displacement of the source during the treatment
Treatment planning
The digitization (catheter reconstruction) was uncom--ment planning resulted in a favorable dose distribution ( Figure 5 ). Figure 5 presents the axial and sagittal slices of the treatment plan. Based on the CT images, it was con--able balloons. That allowed us additional optimization in that region, since the source was positioned centrally with respect to the lumen during the treatment (Figure 6 ). Unsource were identical due to the local uncertainties of the catheter placement from one fraction to the other, the treatment planning resulted in different dwell times in the regions of the balloons, allowing for an additional adjustment of the dose. For instance, in the balloon region (distal target) 100% of the prescription dose was at a distance of 1 cm to 1.8 cm from the source; however, this distance was 1 cm outside the balloon region (proximal target). This indicates that the clinical target volume would receive a lower dose if the patient was treated with the standard EA. Therefore, the plan optimization resulted in an enhanced optimized dose distribution in comparison to the case when a standard esophageal applicator was used. The dosimetry of the Treatment delivery chytherapy treatment in which the applicators are placed transnasally, this BCEA was placed transorally, allowing for less irritation of the nose, nasopharynx, and oropharynx. The applicator stayed in place during the whole multi-fractional course of treatment. The BCEA is designed to be a self-anchoring applicator; however, the po-5 cm 3 of water prior to the delivery of each fraction (Figure 7) to place the catheter centrally while the distance from healthy tissue was maintained; the balloons were emptied after each fraction. Prior to the delivery of each The position of the applicator and the balloon diam--ning CT images and the CT images obtained prior to each fraction. Three methods were used to verify the proper positioning of the BCEA prior to each treatment: a) us--eter in the patient; b) evaluation of the position of 12 rathe CT images, and c) measurements of the diameters of each fraction was less than 6 minutes with a source activity of 9.2 Ci. The patient tolerated the treatment well in the supine position, and did not experience dysphagia or increased discomfort during the treatment.
Discussion
treatment planning, and treatment delivery. The BCEA is in esophageal cancer treatments [1], this allows for maintaining the applicator in place during the whole course consistency of the intra-fractional positioning and the accuracy of the delivery of the intended radiation dose.
Classically, one of the limitations for the deployment of -ed with the placement and tolerance of the transnasal applipain on placement and for the duration of its indwelling.
place for an extended period of time. In the presented case, the applicator stayed in place during the whole multi-fractional course of treatment, which minimizes the possibility for such occurrences. In comparison to the transnasal apturbinates, and nasopharynx are never traversed. This applicator can potentially cause issues if the esophageal mucosa gets compressed between the inof these complications, since the mucosa gets evenly redistributed around the applicator during the treatment.
immediately after delivery of each fraction.
An additional step in treatment plan generation for esophageal cancer was added -dose optimization. This position of the distal 10 cm of the applicator due to the positioning resulted in the possibility to deliver non-uniform dose along the catheter, which could result in an increase of the dose to the cancerous tissue, whereas the minimized. This can be achieved, irrespective of the curvature along the treatment length, since the dwell times can be adjusted to maintain the desired dose distributions. The rigorous dosimetric comparison between the BCEA and EA can be a part of future studies.
Long-term toxicities and the correlation between the of the BCEA are the topics that can be additionally investigated using the data of more patients treated with the novel BCEA and longer follow-up. Due to the limited number of patients, it is not yet possible to conclude if placed applicator. Furthermore, due to the provision to additionally optimize the dose, there exists a possibility of dose escalations for certain patients, depending on their anatomy and the spread of disease. The initial implemenespecially in the determination of the accurate treatment length that would allow the radioactive source to be sent the inaccurate results of this test can potentially offset the whole treatment, causing adverse events. Therefore, the treatment length and BCEA applicator positioning should be evaluated before each fraction.
Conclusions
In this study, the relevant steps in commissioning, assurance for the novel BCEA were presented. The ini--cial in the treatment of the curved anatomy of the lesion due to the improved repeatability and consistency of the balloons assisted in placing the catheter centrally and consistently with respect to the clinical target. A larger -clusions related to the treatment outcome and potential this clinical device.
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